DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Sandhoff Disease (Jatzkewitz-Pilz Syndrome) - Pipeline Review, H1 2017" report to their offering.
Sandhoff Disease (Jatzkewitz-Pilz Syndrome) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Sandhoff Disease (Jatzkewitz-Pilz Syndrome) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Sandhoff disease is an inherited lipid storage disorder that progressively destroys nerve cells (neurons) in the brain and spinal cord. It is caused by a deficiency of the enzyme beta-hexosaminidase. Symptoms include progressive nervous system deterioration, problems initiating and controlling muscles and movement, increased startle reaction to sound, early blindness, seizures, spasticity, and myoclonus. Treatment includes anticonvulsants to control seizures.
The Sandhoff Disease (Jatzkewitz-Pilz Syndrome) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sandhoff Disease (Jatzkewitz-Pilz Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 3 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Key Topics Covered:
- Introduction
- Sandhoff Disease (Jatzkewitz-Pilz Syndrome) Overview
- Therapeutics Development
- Pipeline Products for Sandhoff Disease (Jatzkewitz-Pilz Syndrome) - Overview
- Pipeline Products for Sandhoff Disease (Jatzkewitz-Pilz Syndrome) - Comparative Analysis
- Sandhoff Disease (Jatzkewitz-Pilz Syndrome) - Therapeutics under Development by Companies
- Sandhoff Disease (Jatzkewitz-Pilz Syndrome) - Therapeutics under Investigation by Universities/Institutes
- Sandhoff Disease (Jatzkewitz-Pilz Syndrome) Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Sandhoff Disease (Jatzkewitz-Pilz Syndrome) - Products under Development by Companies
- Sandhoff Disease (Jatzkewitz-Pilz Syndrome) - Products under Investigation by Universities/Institutes
- Sandhoff Disease (Jatzkewitz-Pilz Syndrome) - Companies Involved in Therapeutics Development
- Bioasis Technologies Inc
- Nuo Therapeutics Inc
For more information about this report visit http://www.researchandmarkets.com/research/t8448b/sandhoff_disease
